Kristen Stewart to Join BD as Senior Vice President of Strategy and Investor Relations

Rhea-AI Summary

BD (Becton, Dickinson and Company) announced the appointment of Kristen Stewart as the senior vice president of Strategy and Investor Relations, effective Aug. 31, 2020. Stewart brings nearly two decades of experience in the medical technology sector, having previously led research at Barclays Capital. Her role will focus on enhancing shareholder value and communicating BD's long-term growth strategy. Tom Polen, CEO of BD, expressed confidence in her strategic skills, while Christopher Reidy, CFO, noted her strong investment community ties.

Positive

• Appointment of Kristen Stewart adds significant expertise in medical technology.
• Stewart's role aligns strategy and investor relations, enhancing communication.
• Strong industry recognition for Stewart as a top analyst, boosting investor confidence.

Negative

• None.

FRANKLIN LAKES, N.J., Aug. 17, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Kristen Stewart to the newly created position of senior vice president of Strategy and Investor Relations.

In this role, Stewart will partner closely with the BD executive team to drive shareholder value and to deliver and communicate the company's long-term growth strategy.

Stewart will add to BD her extensive experience as a seasoned health care analyst specializing in medical technology, which she gained working at several premier Wall Street investment banks for nearly two decades. She most recently led the medical technology research franchise at Barclays Capital. She has been recognized by Institutional Investor as one of the top three analysts in the Medical Supplies & Devices category several times during her career.

"As a highly respected analyst in our sector, Kristen brings a deep understanding of the medical technology industry to BD," said Tom Polen, CEO and president. "I am confident her strong strategic and analytical skills will serve the company and our stakeholders tremendously well, and I look forward to her partnership as we continue to execute our strategy."

Stewart said, "I have watched through the analyst lens as BD has transformed into a global medical technology innovator. I am excited by BD's current strategic direction and believe the company has significant potential to optimize shareholder value. I am thrilled to undertake this important new role."

Christopher Reidy, executive vice president, CFO and chief administrative officer, said, "Kristen's wealth of experience and long-standing relationships throughout the investment community will bring meaningful value to BD. I am excited about the alignment of both strategy and IR under Kristen's leadership and look forward to welcoming her to the team."

Stewart began her financial career at PricewaterhouseCoopers. She is a chartered financial analyst and is an inactive certified public accountant.

Stewart will join BD on Aug. 31, 2020 and report to Chris Reidy. 

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.

Contacts:
Kristen Cardillo	Tony Di Meo
BD Public Relations	BD Investor Relations
201.847.5657	201.847.4166
kristen.cardillo@bd.com	Anthony_Di_Meo@bd.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/kristen-stewart-to-join-bd-as-senior-vice-president-of-strategy-and-investor-relations-301113441.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

Who is Kristen Stewart in relation to BD?

Kristen Stewart has been appointed as the senior vice president of Strategy and Investor Relations at BD, effective Aug. 31, 2020.

What is the significance of Kristen Stewart's appointment for BD?

Her appointment is expected to enhance shareholder value and improve communication of BD's long-term growth strategy.

When will Kristen Stewart start her role at BD?

Kristen Stewart will join BD on Aug. 31, 2020.

What experience does Kristen Stewart bring to BD?

Stewart has nearly two decades of experience as a healthcare analyst, specializing in medical technology.

How has Kristen Stewart been recognized in her field?

She has been recognized by Institutional Investor as one of the top three analysts in the Medical Supplies & Devices category multiple times.